Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging
- PMID: 20696179
- DOI: 10.1016/j.neuropharm.2010.07.024
Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging
Abstract
GABA(A) receptor α5-selective inverse agonists enhance cognitive performance in pre-clinical species. However, a key aspect of the clinical development of such compounds is the demonstration that in man such compounds are devoid of the anxiogenic-like activity associated with non-selective inverse agonists such as FG 7142. The triazolophthalazine α5IA (3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine) is an α5-selective inverse agonist which enhances cognitive performance in rodents and encouragingly in human Phase I Safety and Tolerability studies it was devoid of the anxiogenic-like activity associated with FG 7142. However, in order to appropriately interpret this latter observation, it was considered important to demonstrate that the absence of anxiogenic-like activity occurs at significant levels of receptor occupancy. Consequently, the occupancy of human brain GABA(A) receptors was measured using [¹¹C]flumazenil positron emission tomography in three healthy normal young male volunteers following a single oral dose of 2 mg α5IA. One hour after dosing, mean occupancy levels were 53% and this fell to 16% by 8 h post-dose, with the plasma α5IA concentration corresponding to 50% occupancy being 10 ng/mL. These data clearly show that an α5-selective inverse agonist is not associated with anxiogenic-like side effects at doses that give ~50% occupancy.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. doi: 10.1124/jpet.109.157636. Epub 2009 Aug 24. J Pharmacol Exp Ther. 2009. PMID: 19704033
-
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.Pharmacol Ther. 2010 Jan;125(1):11-26. doi: 10.1016/j.pharmthera.2009.09.001. Epub 2009 Sep 19. Pharmacol Ther. 2010. PMID: 19770002 Review.
-
The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.Br J Pharmacol. 2009 Jul;157(5):796-803. doi: 10.1111/j.1476-5381.2009.00216.x. Epub 2009 Apr 30. Br J Pharmacol. 2009. PMID: 19422390 Free PMC article.
-
GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.Curr Top Med Chem. 2011;11(9):1203-14. doi: 10.2174/156802611795371314. Curr Top Med Chem. 2011. PMID: 21050171 Review.
-
Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.J Med Chem. 2004 Jul 1;47(14):3642-57. doi: 10.1021/jm0407613. J Med Chem. 2004. PMID: 15214791
Cited by
-
GABAA Receptor Availability in Relation to Cortical Excitability in Depressed and Healthy: A Positron Emission Tomography and Transcranial Magnetic Stimulation Study.Neuropsychobiology. 2024;83(1):17-27. doi: 10.1159/000535512. Epub 2023 Dec 27. Neuropsychobiology. 2024. PMID: 38151012 Free PMC article.
-
multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated 18F-fluorination.EJNMMI Radiopharm Chem. 2022 Mar 20;7(1):5. doi: 10.1186/s41181-022-00158-z. EJNMMI Radiopharm Chem. 2022. PMID: 35306596 Free PMC article.
-
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors.Curr Top Med Chem. 2016;16(16):1830-42. doi: 10.2174/1568026616666160315142457. Curr Top Med Chem. 2016. PMID: 26975506 Free PMC article. Review.
-
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.Neuropharmacology. 2016 Feb;101:519-30. doi: 10.1016/j.neuropharm.2015.03.002. Epub 2015 Mar 17. Neuropharmacology. 2016. PMID: 25791528 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources